← FDA DRUG APPROVALS

FDA ANDA · ANDA077744

SUMATRIPTAN SUCCINATE

Sponsor: MYLAN

APPLICATION
ANDA077744
TYPE
ANDA
ORIGINAL APPROVAL
2009-08-10
LATEST ACTION
2023-03-31
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SUMATRIPTAN SUCCINATEPrescription
SUMATRIPTAN SUCCINATE EQ 100MG BASE · TABLET · ORAL
SUMATRIPTAN SUCCINATEPrescription
SUMATRIPTAN SUCCINATE EQ 25MG BASE · TABLET · ORAL
SUMATRIPTAN SUCCINATEPrescription
SUMATRIPTAN SUCCINATE EQ 50MG BASE · TABLET · ORAL

Approval history

2023-03-31Labeling · Supplement 13 · standardAP
2021-07-01Manufacturing (CMC) · Supplement 11 · unknownAP
2019-04-16Labeling · Supplement 8 · standardAP
2015-06-19Labeling · Supplement 4 · standardAP
2015-06-19Labeling · Supplement 5 · standardAP
2012-01-11Labeling · Supplement 2AP
2009-08-10OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →